Clinical Trial Update: Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating KITE-753 versus Axicabtagene Ciloleucel for relapsed or refractory diffuse large B-cell lymphoma after first-line therapy; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Axicabtagene ciloleucel (axicabtagene ciloleucel)
• KITE-753

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Relapsed or Refractory Large B-cell Lymphoma | Phase 3 | Status: NOT_YET_RECRUITING